Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus

Thrombosis Research

Volumn 122, Issue 1, 2008, Pages 39-45

  Nomura, Shosaku ^a   Shouzu, Akira ^b   Omoto, Seitarou ^c   Inami, Norihito ^c   Tanaka, Atsushi ^d   Nanba, Masashi ^d   Shouda, Yoshihiro ^e   Takahashi, Nobuyuki ^c   Kimura, Yutaka ^c   Iwasaka, Toshiji ^c  

^a Kishiwada City Hospital   (Japan)

^b Saiseikai Izuo Hospital   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d Baba Memorial Hospital   (Japan)

^e Department of Brain Surgery   (Japan)

Author keywords

Adiponectin; Cell adhesion molecules; Hyperlipidemia; Pitavastatin; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; CD40 LIGAND; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; L SELECTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PITAVASTATIN; RANTES;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; CD40 LIGAND; CELL ADHESION MOLECULES; CHEMOKINE CCL5; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; E-SELECTIN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; P-SELECTIN; QUINOLINES; RECEPTORS, CCR2; REFERENCE VALUES; SMOKING;

EID: 42949160571     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.08.013     Document Type: Article

References (45)

1. Cominacini L., Pasini A.F., Garbin U., Davoli A., De Santis A., Campagnola M., et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 38 (1995) 1122-1124
2. Fries J.W.U., Williams A.J., Atkins R.C., Newman W., Lipscomb M.F., and Collins T. Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am J Pathol 143 (1993) 725-737
3. Davies M.J., Gordon J.L., Gearing A.J., Piqott R., Woolf N., Katz D., et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM-1, and E-selectin in human atherosclerosis. J Pathol 171 (1993) 223-229
4. Beekhuizen H., and van Furth R. Monocyte adherence to human vascular endothelium. J Leukoc Biol 54 (1993) 363-378
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
6. Chobanian A.V. Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia co-exist. Hypertension 18 (1991) 130-131
7. Croft K.D., Beilin L.J., Vandongen R., Rouse I., and Masarei J. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolemia. Atherosclerosis 83 (1990) 101-109
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
9. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1998) 1440-1445
10. Noji Y., Higashikata T., Inazu A., Nohara A., Ueda K., Miyamoto S., et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163 (2002) 157-164
11. Saito Y., Yamada N., Teramoto T., Itakura H., Hata Y., Nakaya N., et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia: dose-finding study using the double-bind, three-group parallel comparison. Arzneimittelforschung 52 (2002) 251-255
12. Han J., Zhou X., Yokoyama T., Hajjar D.P., Gotto Jr. A.M., and Nicholson A.C. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109 (2004) 790-796
13. Han J., Parsons M., Zhou X., Nicholson A.C., Gotto Jr. A.M., and Hajjar D.P. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 110 (2004) 3472-3479
14. Kawakami A., Tani M., Chiba T., Yui K., Shinozaki S., Nakajima K., et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through apoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol 25 (2005) 424-429
15. Kibayashi E., Urakaze M., Kobashi C., Kishida M., Takada M., Sato A., et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci 108 (2005) 515-521
16. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S., and Iwasaka T. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis 18 (2004) 177-185
17. Wang J., Tokoro T., Matsui K., Higa S., and Kitajima J. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci 76 (2005) 2257-2268
18. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
19. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
20. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
21. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
22. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectin. Circulation 100 (1999) 2473-2476
23. Chen H., Montagnani M., Funahashi T., Shimomura I., and Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278 (2003) 45021-45026
24. Hattori Y., Suzuki M., Hattori S., and Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 46 (2003) 1543-1549
25. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemia, Japan Atherosclerosis Society (JAS). Guideline for diagnosis and treatment of hyperlipidemias in adults. Doumyakukouka 25 (1997) 1-34
26. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ECDCDM). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl. 1 (2003) S5-S20
27. 2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes. Blood Coagul Fibrinolysis 16 (2005) 423-428
28. Shimabukuro M., Higa N., Asahi T., Oshiro Y., Takasu N., Tagawa T., et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88 (2003) 3236-3240
29. Nomura S., Inami N., Kimura Y., Omoto S., Shouzu A., Nishikawa M., et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 21 (2007) 38-44
30. Baumgartner-Parzer S.M., Wagner L., Petterman M., Gessl A., and Waldhausel W. Modulation by high glucose of adhesion molecule expression in cultured endothelial cells. Diabetologia 38 (1995) 1367-1370
31. Nomura S., Kanazawa S., and Fukuhara S. Effects of eicosa-pentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with type 2 diabetes mellitus. J Diabet Complications 17 (2003) 153-159
32. Nomura S., Takahashi N., Inami N., Kajiura T., Yamada K., Nakamori H., et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 174 (2004) 329-335
33. Yin W.H., Jen H.L., Chen J.W., Lin S.J., and Young M.S. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab 32 (2006) 229-235
34. Hiuge A., Tenenbaum A., Maeda N., Benderly M., Kumada M., Fisman E.Z., et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27 (2007) 635-641
35. Koh K.K., Quon M.J., Han S.H., Chung W.-J., Ahn J.Y., Seo Y.-H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic hypertensive patients. Circulation 110 (2004) 3687-3692
36. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
37. Maddux B.A., See W., Lawrence Jr. J.C., Goldfine A.L., Goldfine I.D., and Evans J.L. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of α-lipoic acid. Diabetes 50 (2001) 404-410
38. Matsuoka T., Kajimoto Y., Watada H., Kaneto H., Kishimoto M., Umayahara Y., et al. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 99 (1997) 144-150
39. Rudich A., Tirosh A., Potashnik R., Hemi R., Kanety H., and Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47 (1998) 1562-1569
40. Stoll L.L., McCormick M.L., Denning G.M., and Weintraub N.L. Antioxidant effects of statins. Drugs Today 40 (2004) 975-990
41. Chen B., Lam K.S., Wang Y., Wu D., Lam M.C., Shen J., et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 341 (2006) 549-556
42. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004) 1752-1761
43. Erol A. The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins-statins activate the generation of metabolically more capable adipocytes. Med Hypotheses 64 (2005) 69-73
44. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
45. Kim J.B., Sarraf P., Wright M., Yao K.M., Mueller E., Solanes G., et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101 (1998) 1-9